Currently Viewing:
Newsroom
Currently Reading
Bimekizumab Beats Adalimumab in Phase 3 Psoriasis Study
December 18, 2019 – AJMC Staff
Probiotics May Have an Impact on Psoriasis
December 13, 2019 – Gianna Melillo
Research Finds Sex Differences in Links Between Psoriasis and Metabolic Disorders
December 07, 2019 – AJMC Staff
Study Examines Bereavement Stress as Factor in Psoriasis, Atopic Dermatitis
December 04, 2019 – AJMC Staff
Pair of Studies Explore Role of Key Proteins in Psoriasis
November 29, 2019 – Mary Caffrey
Development of PsA Linked to Tenosynovitis in Patients With Arthralgia
November 27, 2019 – Allison Inserro
Patients With Psoriasis See Some Benefit From Disease Education
November 22, 2019 – Allison Inserro
Topline Results Announced for Second Phase 3 Trial of Bimekizumab
November 21, 2019 – Mary Caffrey
Age of Onset Determines Whether Psoriasis or Arthritis Develops First, Study Finds
November 16, 2019 – AJMC Staff

Bimekizumab Beats Adalimumab in Phase 3 Psoriasis Study

AJMC Staff
The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug.
A global phase 3 study, BE SURE, has announced that the bispecific antibody bimekizumab outperformed adalimumab (Humira, AbbVie) in both coprimary end points at week 16, while meeting all secondary end points that measure total skin clearance at 4 and 6 months.

BE SURE found that bimekizumab was superior to adalimumab in achieving 90% improvement in Psoriasis Area and Severity Index (PASI 90) and in Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1). The pharmaceutical company UCB announced the results in a statement.

The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug. BE SURE compared the tumor necrosis factor inhibitor adalimumab, one of the most popular therapies in the world, against an study drug that selectively targets 2 antigens in patients with moderate-to-severe chronic plaque psoriasis.

In this study, the initial treatment period of 24 weeks is followed by a dose-blind maintenance period until week 56. BE SURE enrolled 478 patients with for at least 6 months prior to screening who had psoriasis with an affected surface area of at least 10%, a PASI of a least 12, and an IGA score of at least 3 on a 5-point scale.

Bispecific antibodies, which have the ability to reach 2 therapeutic targets in a synergistic manner, have made news in recent weeks, as the investigational therapy mosunetuzumab was featured at the American Society of Hematology for its effectiveness against malignant B cells.

Bimekizumab is also being studied in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, with the first topline results expected at the end of 2021.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up